drugset
drugset / Trial / NCT02905565

NBP in Adult Patients With Acute Ischemic Stroke (AIS)

NCT02905565 ↗

Phase 2 Completed 177 enrolled CSPC-NBP Pharmaceutical Co., Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a Phase 2 multicenter, randomized, double-blind, placebo-controlled, add-on to standard of care study of NBP softgel capsules for the treatment of mild to moderate AIS in adults.

Timeline

Start
2018-02-28
Primary completion
2020-08-07
Completion
2020-08-07

Drugs

EvaluationDrugModalityDoseRoute
Subject n Butylphthalide Unknown 400 mg Oral

Indications

No indication recorded.